Healthcare / Medical DevicesShanghai
$11.45
-0.29 (-2.47%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $234.5M · quality 76.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
36/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.9B
P/E
30.1x
↑EV/EBITDA
16.9x
↑ROE
8.7%
↑Gross Margin
63.2%
↑Debt/Equity
0.19
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+1.8%
FCF CAGR
+30.9%
FCF margin
19.0%
FCF / Net income
1.07x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.04B · net income $184.2M · FCF $197.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.04B | $1.04B | $1.15B | $1.15B | $983.0M |
| Net Income | $184.2M | $184.2M | $345.4M | $328.6M | $251.5M |
| EBITDA | $221.1M | $221.1M | $420.3M | $375.5M | $283.2M |
| EPS | 0.43 | 0.43 | 0.81 | 0.77 | 0.60 |
| Gross Margin | 63.2% | 63.2% | 67.2% | 63.0% | 58.5% |
| Operating Margin | 18.1% | 18.1% | 31.8% | 30.9% | 23.0% |
| Net Margin | 17.8% | 17.8% | 30.1% | 28.7% | 25.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.19 | 0.19 | 0.29 | 0.14 | 0.09 |
| Current Ratio | 4.34 | 4.34 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $197.5M | $197.5M | $234.5M | $255.2M | $88.1M |
| Returns | |||||
| ROE | 8.7% | 8.7% | 16.8% | 18.3% | 17.5% |
| Valuation | |||||
| P/E | 30.13 | 30.13 | 17.72 | 26.77 | 32.30 |
| EV/EBITDA | 16.87 | 16.87 | 11.89 | 20.58 | 25.86 |
| P/B | 2.32 | 2.32 | 2.98 | 4.89 | 5.64 |
| Growth & Yield | |||||
| Revenue Growth | -9.6% | -9.6% | 0.2% | 16.5% | — |
| EPS Growth | -46.9% | -46.9% | 5.2% | 28.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
33.2%
EPS terminal req.
$1.02
Spread vs growth
-80.1%
5Y implied EPS CAGR
23.4%
EPS terminal req.
$1.23
Spread vs growth
-70.3%
10Y implied EPS CAGR
16.5%
EPS terminal req.
$1.98
Spread vs growth
-63.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-14.0%
Start / end P/E
16.4x → 26.6x
EPS bridge
0.81 → 0.43
Residual
-29.1%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.